Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
The leading professional organisation for medical oncology
Get acquainted with the candidates running for the ESMO Presidency and the three Director positions and familiarise yourself with their ideas on how they see the future of ESMO
Come and take an active part by submitting your abstract to the leading global meeting dedicated to precision oncology.
Online application is open until 31 May 2022
Meet us in Paris to interact with key opinion leaders and learn first-hand about practice challenges and controversies in oncology
Learn best practice recommendations for the treatment of this tumour type in this condensed, accessible format
The abstract submission system is now open for the ESMO Asia Congress 2022, the best scientific platform in Asia-Pacific to present your cutting-edge oncology research. Live in Singapore on 2-4 December 2022.
We are finally back to Barcelona for four exciting days of unparalleled presentations unveiling new horizons in the treatment of GI malignancies.
Stay up to date with the most recent data in multiple myeloma
A validated and reproducible tool to assess the magnitude of clinical benefit for cancer medicines.
The ESMO-EANM Advanced Course will take place in Essen, Germany
From ESMO Breast Cancer 2022:
For patients with hormone receptor-positive, HER2-negative advanced breast cancer, the addition of ribociclib to fulvestrant continues to significantly improves overall survival after more than 70 months
Read more about how the global oncology community is responding to the humanitarian crisis
An ESMO statement was delivered by the ESMO Director of Public Policy, Rosa Giuliani, on the topic of ‘Follow-up to the political declaration of the third high-level meeting of the General Assembly on the prevention and control of non-communicable diseases’ during the World Health Assembly (WHA75), 22-28 May 2022
An ESMO statement was delivered by the ESMO Director of Public Policy, Rosa Giuliani, on the topic of ‘The Public Health Dimension of the World Drug Problem’, during the World Health Assembly (WHA75), 22-28 May 2022.
An ESMO statement was delivered by the ESMO President, Solange Peters, on the topic of Human Resources for Health, during the World Health Assembly (WHA75), 22-28 May 2022.
New indication concerns the treatment of adult patients with relapsed or refractory follicular lymphoma
ESMO is pleased to announce the first translation of the Patient Guides in the Czech language
Findings from the NCI-MATCH tumour-agnostic platform subprotocol study
An academic clinical decision support system to better address the challenges of delivering biomarker-driven oncology
New indication concerns the adjuvant treatment of patients with early-stage non-small cell lung cancer
Long-term nucleos(t)ide analogue treatment associated with lower risk of extrahepatic malignancy development among patients with chronic hepatitis B
A translational analysis of the DAISY trial improves knowledge on the mechanisms of action of the antibody–drug conjugate
In the SASCIA trial, sacituzumab govitecan was associated with a higher incidence of adverse events and dose delays than treatment of physician’s choice in patients with HER2-negative breast cancer at high risk of relapse, but dose reductions occurred with a similar frequency in both arms
Results from the VIOLETTE trial also suggest that mutation status may influence response to each agent
Two studies hint at a lack of effect of palbociclib on ovarian function and demonstrate similar reduced recurrence with abemaciclib regardless of menopausal status
Two studies show that quality of life was maintained or improved with new treatments for advanced breast cancer
In her Keynote Lecture at ESMO Breast Cancer 2022, Prof. Sibylle Loibl looks at neoadjuvant therapy and the fertility and pregnancy issues facing young women with breast cancer
The value of genomic testing is being increasingly demonstrated and will evolve over time
Although bilobectomy remains a valid procedure, comparatively high mortality rates indicate that cautious use and appropriate patient counselling is required
Findings from the PACIFIC-6 trial echo the benefits seen with durvalumab after concomitant chemoradiotherapy, representing a potential alternative for vulnerable and older patients
New indication concerns the treatment of adult patients with relapsed or refractory follicular lymphoma
Findings from the NCI-MATCH tumour-agnostic platform subprotocol study
An academic clinical decision support system to better address the challenges of delivering biomarker-driven oncology
New indication concerns the adjuvant treatment of patients with early-stage non-small cell lung cancer
Long-term nucleos(t)ide analogue treatment associated with lower risk of extrahepatic malignancy development among patients with chronic hepatitis B
Findings from a population-based study in 9 European countries
The review follows interim results from the ongoing ARIEL4 study indicating that overall survival was shorter in patients treated with rucaparib than in those who received chemotherapy
Findings from analysis of incidence trends for 12 cancer types
It is intended for the treatment of adult patients with relapsed or refractory follicular lymphoma
The evidence-based tool is designed to help interpret data from a heterogeneous research landscape
The ESMO Breast Cancer Congress 2022, the annual event dedicated to advancing the science, disseminating education and improving the practice of breast cancer specialists worldwide, will focus this year on integrating translational research for innovative clinical practice.
A consensus reached by a lung clinical community within the International Cancer Benchmarking Partnership (ICBP), presented at the ELCC, 30 March – 2 April 2022, has highlighted international disparities in management and outcomes of patients with lung cancer in high-income countries, and has provided a roadmap of key actions that should be taken to homogenise practices, help enable earlier diagnosis and offer equitable access to care.
More than half of patients diagnosed with advanced non-small cell lung cancer (NSCLC) undergo biomarker testing, and this figure has increased over the last five years, reveal real-world data from a Spanish national registry study reported at the European Lung Cancer Congress (ELCC), 30 March-2 April 2022.
The European Lung Cancer Congress 2022 (ELCC), the annual event dedicated to advancing the science, disseminating education and improving the practice of lung cancer specialists worldwide, will be held as a virtual meeting.
Original data presentations by the authors of the OlympiA and PEARLS/KEYNOTE-091 trials will be followed by critical analysis and discussion with a panel of renowned experts.
ESMO announces a new series of resources designed to guide physicians in areas of oncological practice not covered by guidelines, where current evidence is insufficient to evenly inform clinical decision-making
The ESMO Targeted Anticancer Therapies Congress 2022, designed for basic scientists, physicians and translational researchers belonging to academic settings, industry and regulatory agencies will be held as a virtual meeting.
ESMO has announced today that the 2022 ESMO Breast Cancer Award is presented to Sibylle Loibl for her exceptional contribution to clinical research in breast cancer.
In light of the challenging situation in Prague due to the ongoing arrival of refugees from Ukraine
ESMO expresses profound sadness about the unfolding tragedy in Ukraine and the suffering of people
The 2022 ESMO Heine H. Hansen Award is conferred on Fred R. Hirsch for his lifelong outstanding contribution to lung cancer research
Who will be the next ESMO Awardees? Submit your nominations before 9 March.
Based on current knowledge available, they address key questions on safety and efficacy of COVID-19 vaccines, their interference with anticancer treatment, and advocate for a global strategy for the booster dose
ESMO President will act as an Advisor
ESMO has announced today that the 2022 ESMO TAT Honorary Award is presented to Lesley K Seymour
ESMO delivered an official statement at the Special Session of the World Health Assembly to strengthen pandemic prevention, preparedness and response
Supporting your clinical decisions with ESMO’s regularly updated Clinical Practice Guidelines and consensus recommendations, developed by the leading experts in our profession.
The ESMO-EANM Advanced Course will take place in Essen, Germany
The courses include state of the art lectures, workshops and interactive discussion seminars
A globally visible platform to publish scientific studies and a source of educational updates.
A range of publications that can be browsed online by all ESMO members and downloaded for offline use
Belgium
Spain
Switzerland
Switzerland
Spain
Switzerland
Czech Republic
France
Participate in our collegial events with leaders in the field and get the chance to collaborate
with prominent European cancer institutions.
Take the chance to grow as a clinician-scientist and to explore research in oncology: submit your application by 19 June 2022!
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
